|
Published in the
Bulletin of Experimental Treatments for AIDS January 1999 issue,
by the San Francisco AIDS Foundation.
-- Main Page
-- Top Conference Stories
-- Treatment Guidelines and Immune-Based Therapies
-- Protease Inhibitor Complications And Side
Effects
-- HIV Viral Load, Resistance Testing, and Adherence
-- Anti-HIV Drugs And Combinations
-- Opportunistic And Other Conditions
-- Women And Pregnancy, Miscellaneous
January
1999 Table of Contents
Main Page
beta@sfaf.org
|
|
Highlights from Recent Conferences
-- Top Conference Stories
Harvey S. Bartnof, MD
- U.S. Department of Health and Human Service updates HIV treatment
guidelines.
- Center for Disease Control and Prevention (CDC) updates treatment
guidelines for people with active tuberculosis who are taking HAART.
- HAART plus cytokines can help to flush HIV from resting "reservoir"
cells, but some HIV DNA remains.
- Efavirenz (Sustiva) can cause a false-positive screening test for
cannabinoids (marijuana).
- Efavirenz increases total and high density lipoprotein (HDL) "good"
cholesterol.
- After failure of an amprenavir/AZT/3TC regimen, "salvage therapy"
with either indinavir/nevirapine/d4T/3TC or saquinavir/ritonavir/d4T/ddI
may be successful.
- Interleukin-2 (IL-2) causes low thyroid hormone levels in 10% of
people.
- After starting HAART, the risk of shingles (herpes zoster) temporarily
increases.
- HAART may increase the rate of warts in people with HIV.
- High blood lipid (fat) levels associated with HAART respond to therapy
with gemfibrozil (Lopid) and/or atorvastatin (Lipitor).
- Men taking a protease inhibitor may develop female-appearing breasts.
- Congenital clubfoot may be a birth defect associated with maternal
use of HAART.
- HIV viral load response after one year of therapy may be predicted
by viral load at 8-12 weeks.
- A high HIV viral load is associated with poor adherence to HIV therapy.
- People may be able to tolerate ritonavir (Norvir) better if they
have normal body fat and are taking vitamin and mineral supplements.
- Ritonavir is used for a non-HIV-related indication.
- Nevirapine (Viramune) causes opiate withdrawal in seven people on
methadone maintenance.
- One hundred and thirty-two San Franciscans have taken post-exposure
prophylaxis (PEP) after HIV exposure related to unprotected sex or
sharing of injection works.
- AIDS-related dementia is linked with Alzheimer’s disease gene.
- A decrease in hepatitis C viral load may occur after one year of
anti-HIV HAART.
- Neither acupuncture nor amitriptyline (Elavil) show benefits over
placebo for treating HIV-related peripheral neuropathy.
- The lowest (nadir) CD4 count before anti-HIV therapy correlates
with future risk for Pneumocystis carinii pneumonia (PCP).
- Candida yeast infection in HIV positive women correlates
better with HIV viral load than with CD4 cell count.
- A sample of over 1,000 U.S. mothers who had just given birth had
poor HIV/AIDS knowledge scores.
Page last updated 15 January 1999
|
